Elo Mutual Pension Insurance Co Has $9.32 Million Holdings in Cencora, Inc. $COR

Elo Mutual Pension Insurance Co raised its position in shares of Cencora, Inc. (NYSE:COR) by 28.1% in the third quarter, Holdings Channel reports. The fund owned 29,808 shares of the company’s stock after buying an additional 6,535 shares during the quarter. Elo Mutual Pension Insurance Co’s holdings in Cencora were worth $9,316,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also made changes to their positions in COR. Mirae Asset Global Investments Co. Ltd. grew its position in Cencora by 13.0% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 48,270 shares of the company’s stock worth $15,086,000 after purchasing an additional 5,543 shares during the last quarter. Acadian Asset Management LLC boosted its stake in shares of Cencora by 947.5% in the 2nd quarter. Acadian Asset Management LLC now owns 257,082 shares of the company’s stock valued at $77,069,000 after purchasing an additional 232,539 shares in the last quarter. Mediolanum International Funds Ltd grew its stake in Cencora by 133.0% during the third quarter. Mediolanum International Funds Ltd now owns 56,293 shares of the company’s stock worth $17,342,000 after buying an additional 32,138 shares during the last quarter. Advisors Asset Management Inc. increased its holdings in Cencora by 40.3% during the 3rd quarter. Advisors Asset Management Inc. now owns 17,302 shares of the company’s stock valued at $5,407,000 after purchasing an additional 4,973 shares in the last quarter. Finally, Rhumbline Advisers increased its stake in shares of Cencora by 4.0% in the third quarter. Rhumbline Advisers now owns 430,150 shares of the company’s stock valued at $134,435,000 after buying an additional 16,539 shares in the last quarter. Institutional investors and hedge funds own 97.52% of the company’s stock.

Insiders Place Their Bets

In other news, CEO Robert P. Mauch sold 5,096 shares of Cencora stock in a transaction on Tuesday, January 20th. The shares were sold at an average price of $354.73, for a total transaction of $1,807,704.08. Following the transaction, the chief executive officer owned 66,726 shares in the company, valued at approximately $23,669,713.98. The trade was a 7.10% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Elizabeth S. Campbell sold 3,351 shares of the firm’s stock in a transaction on Friday, December 19th. The stock was sold at an average price of $342.10, for a total value of $1,146,377.10. Following the transaction, the executive vice president directly owned 23,891 shares of the company’s stock, valued at approximately $8,173,111.10. This represents a 12.30% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 15,220 shares of company stock valued at $5,282,867 in the last ninety days. 0.38% of the stock is currently owned by insiders.

Cencora Stock Performance

COR opened at $371.86 on Monday. The business’s fifty day moving average is $351.72 and its 200-day moving average is $334.19. The firm has a market cap of $72.34 billion, a P/E ratio of 44.69, a price-to-earnings-growth ratio of 1.73 and a beta of 0.68. The company has a debt-to-equity ratio of 3.62, a quick ratio of 0.51 and a current ratio of 0.92. Cencora, Inc. has a 52-week low of $248.59 and a 52-week high of $377.54.

Cencora (NYSE:COR) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $4.08 EPS for the quarter, topping analysts’ consensus estimates of $4.04 by $0.04. The company had revenue of $85.93 billion during the quarter, compared to analysts’ expectations of $86.12 billion. Cencora had a return on equity of 176.54% and a net margin of 0.50%.Cencora’s revenue was up 5.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned $3.73 EPS. Sell-side analysts expect that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, March 2nd. Stockholders of record on Friday, February 13th will be paid a $0.60 dividend. The ex-dividend date of this dividend is Friday, February 13th. This represents a $2.40 annualized dividend and a dividend yield of 0.6%. Cencora’s dividend payout ratio is currently 28.85%.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. Weiss Ratings raised shares of Cencora from a “hold (c+)” rating to a “buy (b)” rating in a report on Thursday, February 5th. Barclays boosted their target price on Cencora from $400.00 to $425.00 and gave the company an “overweight” rating in a research note on Friday, February 13th. Mizuho increased their price objective on shares of Cencora from $340.00 to $380.00 and gave the stock an “outperform” rating in a research report on Thursday, November 6th. Bank of America reduced their target price on shares of Cencora from $380.00 to $360.00 and set a “neutral” rating for the company in a report on Monday, January 5th. Finally, Jefferies Financial Group upgraded Cencora from an “underperform” rating to a “buy” rating in a research note on Thursday, January 22nd. Eleven analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $399.00.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.